



2016 Annual Report amfAR, The Foundation for AIDS Research

Contents

amfAR in 2016	01
Grants, Fellowships, and Awards	07
Research Grants, Fellowships, and Awards	
TREAT Asia Grants and Awards	
GMT Initiative Awards	
Public Policy Awards	
Financial Highlights	13
Leadership and Advisory Committees	15
Board of Trustees	
Scientific Advisory Committee	
Program Advisory Council	
Management Group	

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research.



amfAR CEO Kevin Robert Frost flanked by Dr. Paul Volberding, director of the amfAR Institute for HIV Cure Research (left), and amfAR Chairman Kenneth Cole

Research

Countdown to a Cure for AIDS

In 2015, amfAR announced a \$100 million investment strategy to support its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure by 2020. The strategy represents an unprecedented expansion of amfAR's grant making and is designed to provide support to any scientist or team of investigators for any research idea with the potential to advance the search for a cure, at any stage of its development.

In just the first 24 months of the initiative, amfAR has supported 139 principal investigators and key personnel in 16 U.S. states and nine other countries around the world. Structured to provide sustained support for a wide range of studies that advance both emerging and established ideas, the strategy comprises the following components:

- The amfAR Institute for HIV Cure Research, established in 2016 with a \$20 million grant over five years to the University of California, San Francisco (UCSF), is the cornerstone of amfAR's cure research efforts.
- Innovation Grants, two-year awards of up to \$200,000 each that enable researchers to test innovative ideas supported by limited preliminary data.
- Impact Grants of up to \$2 million each over four years support the in-depth development of concepts already underpinned by preliminary data showing genuine potential for achieving a cure.
- Investment Grants are aimed at recruiting the experience and expertise of scientists from outside the field of HIV. These \$1 million grants are awarded over a four-year period. Grantees may have expertise in fields such as cancer, neuroscience, or inflammatory disease that can directly inform efforts to cure HIV.

- ARCHE, the amfAR Research Consortium on HIV Eradication, was launched in 2010. It supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies.
- ► The Opportunity Fund is a funding mechanism that enables amfAR to respond quickly to emerging and unforeseen research opportunities.

Innovation Grants

In June 2016, amfAR announced a new round of Innovation Grants, totaling close to \$1.4 million, to allow scientists to better understand why HIV persists in the body despite effective antiretroviral therapy and pursue novel pathways to a cure. The grants were supported in part by the Foundation for AIDS and Immune Research (FAIR). Among the grantees are Dr. Jonathan Karn of Case Western Reserve University in Cleveland, who is aiming to develop a more accurate, cost-effective, and efficient way to measure the size of the viral reservoir; Dr. Maud Mavigner of Emory University in Atlanta, who is conducting a comprehensive study to identify the most accurate methods to measure the viral reservoir in rhesus macaques infected with SIV (the simian form of HIV); and Dr. Celsa Spina of the University of California, San Diego, who is studying how and where HIV inserts itself into our DNA, enabling it to establish the hidden viral reservoir.

Investment Grants

In January 2016, amfAR awarded \$1 million each over four years to Harvard physicist Dr. David Weitz and bioengineer and polymer scientist Dr. Alexander Zelikin of Aarhus University in Denmark. The two are collaborating with leading HIV researchers Drs. Bruce Walker and Martin Tolstrup at Harvard and Aarhus, respectively, in their efforts to eradicate the viral reservoir, which is considered the principal barrier to curing HIV.


ARCHE (amfAR Research Consortium on HIV Eradication)

In October 2015, amfAR provided \$850,000 of renewal ARCHE funding to a consortium of European researchers who aim to replicate the case of the "Berlin patient," the first and only person known to have been cured of HIV. Diagnosed with leukemia, the patient was given a stem cell transplant with a twist: the cells he received were taken from a donor with a rare genetic mutation conferring resistance to HIV infection. Led by Dr. Javier Martínez-Picado of IrsiCaixa in Spain and Dr. Annemarie Wensing of University Medical Center Utrecht in the Netherlands, the team has already identified a group of patients who have undergone transplants and continues to monitor their progress in the hopes of generating new knowledge that can inform more widely applicable interventions.

amfAR also awarded a \$672,000 ARCHE grant in June 2016 to support a research team led by Dr. Timothy Schacker of the University of Minnesota, Minneapolis. Schacker is collaborating with a pair of leading investigators from the amfAR Institute for HIV Cure Research, Drs. Steven Deeks and Peter Hunt of the University of California, San Francisco (UCSF), to address one of the greatest challenges in HIV cure research: how to establish whether a person has been cured.

Mathilde Krim Fellowships

In October 2015, amfAR awarded a total of \$600,000 in Mathilde Krim Fellowships in Basic Biomedical Research, which provide funding for exceptional young researchers who are new to the field of HIV/AIDS research. The program, which was created in 2008 in honor of amfAR's Founding Chairman Dr. Mathilde Krim, has achieved spectacular results, including numerous published studies in major scientific journals. Each Krim Fellow receives \$150,000 over two years.



amfAR Institute for HIV Cure Research scientist Dr. Nadia Roan of the University of California, San Francisco (UCSF)

The 2016 fellows are Dr. Luis Agosto of Boston Medical Center, who is exploring one of the mechanisms that perpetuates the viral reservoir, with the goal of understanding how the virus evades the immune system; Dr. Liang Shan of Yale University, who is using a humanized mouse model to test the efficacy of latency reversing



Dr. Javier Martínez-Picado of IrsiCaixa in Spain

drugs, studying their ability to reactivate HIV so that the immune system can kill those cells that harbor the virus; Dr. Louise Scharf of the California Institute of Technology in Pasadena, who is studying the molecular structure of broadly neutralizing antibodies isolated from two HIV-infected patients to better understand how these powerful antibodies can help in the development of a vaccine against the virus; and Dr. Amit Sharma of the Fred Hutchinson Cancer Research Center in Seattle, who is investigating how rhesus macaques can be better utilized as an animal model in HIV vaccine studies.

Published Research

Research studies make the greatest impact on the HIV/AIDS field and on the broader scientific community when they are published in scientific journals. In FY2016, 64 scientific publications resulted from amfAR-funded research.

HIV Cure Summit

In December 2015, amfAR held its second annual HIV Cure Summit at the University of California, San Francisco (UCSF), where leading amfAR-funded HIV cure researchers reported on their progress and discussed the scientific challenges that continue to stand in the way of a cure. The summit followed a November 30 press conference announcing the establishment of the amfAR Institute for HIV Cure Research with a \$20 million grant over five years to UCSF. Speaking at the summit, Drs. Warner Greene, Mike McCune, Satish Pillai, and Steven Deeks addressed the four pillars of HIV cure research: charting the locations of latent HIV reservoirs; understanding how these pockets of virus are established and maintained; recording the amount of virus they contain; and finding a way to eliminate them.

Think Tanks

In March 2016, amfAR hosted a think tank in Memphis, TN, on measuring the latent HIV reservoir. One of the central challenges in determining whether a person has been cured is measuring small amounts of virus in difficult-to-find niches. The researchers discussed multiple approaches to address the issue and helped design a project that amfAR funded in June 2016, which is being led by think tank participant Dr. Timothy Schacker of the University of Minnesota, Minneapolis.

amfAR hosted another think tank in Portland, OR, in June 2016, on gene therapy approaches to curing HIV. While pharmacological and immunological approaches remain the dominant cure strategies, the case of the "Berlin patient"—the first and only person known to have been cured of HIV—points to the promise of gene therapy. The 10 researchers discussed the various gene therapy strategies currently being pursued and developed recommendations for further advancing the field.

TREAT Asia

amfAR's TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV treatments to adults and children across the Asia-Pacific through research, education, and advocacy of evidence-based HIV-related policies. The TREAT Asia Network encompasses 21 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced a record 34 publications in peer-reviewed medical journals in 2016.

Gathering Critical Information

TREAT Asia pioneered the region's first adult observational database for HIV/AIDS—the TREAT Asia HIV Observational Database (TAHOD)—which now includes anonymous data collected from approximately 10,000 patients at 21 clinical sites in 12 countries. The information gathered and analyzed through the



Participants at the May 2016 hepatitis C and HIV co-infection treatment training in Bangkok

database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. The TAHOD-Lite database, launched by TREAT Asia in 2015, includes more basic data but from a much larger proportion of the HIV-positive patients seen at participating sites.

A Global Collaboration

For the past 10 years, amfAR's TREAT Asia program has been leading the Asia-Pacific region's involvement in the U.S. National Institutes of Health's (NIH's) global HIV consortium, leDEA—the International Epidemiologic Databases to Evaluate AIDS. In 2016, amfAR successfully re-competed for funding for a new five-year cycle. Studies will be conducted across 58 institutions in 13 countries to address emerging and critical issues facing people living with HIV who are transitioning from pediatric to adolescent care, and aging into older adults.

The new funding will also expand TREAT Asia's research portfolio to evaluate mental health issues for adolescents, explore how amphetamine use impacts HIV risk behaviors among men who have sex with men and transgender individuals, and enhance the use of eHealth technologies to engage and retain people in treatment programs.

Improving Care for Children

TREAT Asia's Pediatric Network includes 20 sites in six countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database was modeled on the adult database and includes data from more than 6,400 pediatric patients in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam.

Adolescent Research

There has been growing recognition that the global HIV community has not done enough to prepare patients, families, and providers for the transition of children into adult life and from pediatric to adult HIV care. TREAT Asia is helping to develop and fund adolescent transition programs with the Children and Youth Program of SEARCH (South East Asia Research Collaboration on HIV) at the Thai Red Cross AIDS Research Centre (TRC-ARC) with additional funding from LIFE+ and the International AIDS Society's Collaboration on Paediatric HIV Education and Research (CIPHER) initiative. In 2016, TREAT Asia/amfAR was awarded a two-year Developmental Research Grant by the National Institutes of Health (NIH) to improve the collection of data on adolescent transition in Malawi, South Africa, and Thailand.

In 2016, three TREAT Asia investigators, Drs. Tavitiya Sudjaritruk, Suvaport Anugulruengkitt, and Watsamon Jantarabenjakul, were awarded prestigious grants under the CIPHER initiative to research medical problems experienced by HIV-positive youth. In addition, Dr. Nadia Kancheva-Landolt of HIV-NAT at the TRC-ARC conducted several studies aimed at improving the reproductive health of HIV-positive young women in Thailand, with funding from ViiV Healthcare. TREAT Asia has also been following 248 HIV-infected adolescents at nine sites in Malaysia, Thailand, and



The Thai Red Cross AIDS Research Centre's Drs. Nittaya Phanuphak and Praphan Phanuphak at the launch of the Adam's Love Clinic in Bangkok

Vietnam to evaluate social, cultural, and behavioral factors that affect treatment adherence. The study, which is being funded by LIFE+, uses an audio computer-assisted self-interview instrument.

Expanding Pre-Exposure Prophylaxis (PrEP) in Thailand

In 2016, amfAR funded a study to assess combination HIV prevention needs, including pre-exposure prophylaxis (PrEP) among female sex workers in Bangkok and Pattaya, Thailand. The research team brings together experts from the Service Workers in Group (SWING) Foundation, a Thai advocacy organization for sex workers; Institute for Population and Social Research at Mahidol University in Bangkok; Johns Hopkins Bloomberg School of Public Health; and amfAR.

Addressing Unmet Needs in HIV Care

In January 2016, TREAT Asia embarked on a think tank project to identify and address gaps in the management of HIV in Asia. The project includes over 20 experts in HIV and other sub-specialties from a dozen countries in the region. The think tanks are focusing on three priority areas: HIV and cardiovascular disease, HIV and liver disease, and HIV and drug resistance.

Mobilizing HIV-Positive Youth

In February and May 2016, TREAT Asia held two Youth ACATA (Asia Community for AIDS Treatment and Advocacy) workshops in Bangkok for young people living with HIV from Cambodia, Indonesia, and Thailand. Launched in 2015 with support from ViiV Healthcare's Positive Action for Adolescents program, Youth ACATA aims to educate participants about HIV and antiretroviral therapy and connect them to other HIV-positive youth in the region.

Promoting Treatment Access for GMT

In late 2015, with partial funding from amfAR, the Thai Red Cross AIDS Research Centre launched the Adam's Love Clinic for gay men, other men who have sex with men, and transgender individuals (collectively, GMT), as well as the Tangerine Community Health Centre—Southeast Asia's first transgender-specific sexual health clinic—both in Bangkok.

Taking on Hepatitis C Co-Infection

In May 2016, TREAT Asia co-sponsored a training session in Bangkok for clinicians on treating hepatitis C and HIV co-infection with direct-acting antivirals. TREAT Asia conducted the training in collaboration with the International Network for Hepatitis in Substance Users and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. In August 2016, TREAT Asia hosted its fourth regional strategic meeting on hepatitis C virus treatment access with 22 participants from key population regional networks in eight Asian countries.

Public Policy

Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. Through its Public Policy Office in Washington, DC, amfAR educates policymakers, the media, and the public about evidence-based policies to address HIV/AIDS in the U.S. and around the world.

Shaping the Domestic Response to HIV/AIDS

In February 2016, amfAR published an infographic titled *Small Increase, Big Impact,* illustrating the declining purchasing power of the National Institutes of Health's (NIH) HIV/AIDS research dollars. In 2016, the NIH budget was increased by \$2 billion, and President Obama proposed a further increase of \$825 million for 2017. However, HIV research funding remained at 2015 levels. An increase in HIV research funding in line with the increase in total NIH funding would have meant an additional \$76.6 million for HIV research for 2017. Such an increase would have allowed the NIH to fund 180 HIV/AIDS studies that could significantly advance HIV prevention, treatment, or cure research; 51 clinical trials focused on curing HIV; or a breakthrough prevention trial.



amfAR's Christina Chandra, Jack MacAllister, and Jennifer Sherwood pose with the Public Policy Office's posters and publications at the 2016 International AIDS Conference in Durban, South Africa.

Key Populations

amfAR is dedicated to addressing the needs of the people most vulnerable to HIV infection: men who have sex with men, sex workers, people who inject drugs, and transgender individuals. In October 2015, amfAR published *Towards Defining an HIV Implementation Science Agenda for Key Populations in Low- and Middle-Income Countries* based on a meeting the Foundation hosted in May 2015 to brainstorm how implementation science

research might improve HIV outcomes for key populations in resource-limited settings. amfAR published *Following the Money to Key Populations, National Priorities, and Evidence-Based Budgeting* in June 2016. This report is a qualitative assessment of how Kenya and South Africa use health data for budgetary resource allocation.

In July 2016, amfAR published *Is PEPFAR Funding for Key Populations Aligned with the Epidemiologic Burden?* This report is based on an evaluation of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Worldwide, 40–50% of all HIV infections in adults aged 15–49 occur among key populations. The report concluded that the disproportionate HIV risk, along with poor quality health services, underscores the continuing importance of prioritizing resources and targeted interventions.

Global Health

In FY2016, amfAR published *The World Without PEPFAR*, an infographic highlighting significant advances in global HIV/AIDS treatment and prevention made possible by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Launched in 2003, PEPFAR made billions of dollars available for HIV programs in developing countries and fundamentally changed the course of the global epidemic.

amfAR also added new features and data to its PEPFAR Country/ Regional Operational Plan database, a comprehensive, navigable database of PEPFAR's planned funding of HIV/AIDS activities from 2007 to 2015. Launched in 2015, the database is designed to help civil society organizations, ministries of health and finance, researchers, and other stakeholders access and understand PEPFAR's programs and priorities on a deeper level than was possible using other platforms.

The GMT Initiative

Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men, and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to grassroots groups, amfAR has expanded access to HIV education and prevention services; supported advocacy aimed at increasing funding for prevention and treatment services; and worked to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS.

Implementation Science Awards

In FY2016, amfAR's grant making through the GMT Initiative evolved to support larger implementation science projects aimed at identifying barriers to HIV testing, treatment, and care and studying the impact of innovative HIV service delivery models for GMT in lowand middle-income countries. amfAR has awarded \$2.6 million over three years to support three such studies.

► Dr. Chris Beyrer of Johns Hopkins University is leading a team of researchers and community-based services (in collaboration with the International HIV/AIDS Alliance Myanmar) in evaluating the effectiveness of promising interventions for GMT in Myanmar, where increased HIV testing and treatment opportunities are becoming available. The researchers are assessing the



Kaung Htet Thu of the International HIV/AIDS Alliance Myanmar

effectiveness of HIV self-testing done in the privacy of one's home, point-of-care CD4 testing, and the use of "peer navigators" familiar with the local health system to help those newly diagnosed gain access to HIV treatment and care.

- In Lima, Peru, Dr. Javier Lama of Asociación Civil Impacta Salud y Educación and his team are aiming to improve the continuum of care among transgender women by using an innovative model that integrates HIV prevention and treatment services with transgender-affirming medical care.
- And in Bangkok, Dr. Nittaya Phanuphak and her team at the Thai Red Cross AIDS Research Centre are working to show how innovative technologies such as GMT-targeted websites that incorporate online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment programs.

amfAR HIV Scholars Program

In FY2016, amfAR supported four young researchers from Paraguay, Brazil, South Africa, and Indonesia undergoing five months of graduate-level public health study at the Center for LGBT Health Research at the University of Pittsburgh Graduate School of Public Health as part of the amfAR HIV Scholars Program. The program aims to strengthen GMT community-based research and responses to HIV, often in areas where little data about HIV among GMT currently exist and where stigma and discrimination deter many from seeking HIV testing and services. The 2016 amfAR HIV Scholars are Dr. Antonio Spagnolo of the National University of Asunción in Paraguay; Daniel Dutra de Barros of Santa Casa de São Paulo School of Medical Sciences in Brazil; Kabelo Maleke of Project Boithato at the Anova Health Institute in rural South Africa; and Adi Nugroho of the GWL-INA Network in Jakarta, Indonesia.

Public Information

amfAR seeks to translate and disseminate information on important HIV/AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to increase broad awareness and knowledge of the pandemic. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for HIV.

Educational Materials

amfAR produces a range of periodicals in both print and electronic formats, including its newsletter *Innovations*, published twice a year and distributed to more than 45,000 people; the *TREAT Asia Report*, an email newsletter distributed six times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to nearly 100,000 people. The Foundation's website, which attracts an average of 40,000 visitors per month, features news, interviews, and original articles covering HIV/AIDS research, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the general public.

Social Media

amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly adds content to its Facebook page, live tweets from events, and posts images on Instagram from fundraising and program events. amfAR has 72,000 likes on Facebook, 40,000 Twitter followers, and more than 108,000 Instagram followers.

Media Outreach

In 2016, amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV/AIDS-related press coverage. Articles and reports involving amfAR—many of which included interviews with amfAR staff and spokespeople—were carried in numerous media outlets, including *The New York Times, Forbes, The Advocate*, the *South China Morning Post,* CBS Radio, Reuters, and Bloomberg News.

Enlisting the Help of Public Figures

amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, amfAR's Founding International Chairman, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Campaign Chair Sharon Stone.

Other celebrity supporters included amfAR Ambassadors Milla Jovovich, Michelle Yeoh, and Cheyenne Jackson, Kathy Bates, Angela Bassett, Julia Roberts, Matt Bomer, Jamie Lee Curtis, Diane von Furstenberg, Gwyneth Paltrow, Chiara Ferragni, Ryan Murphy, Lady Gaga, Diane Kruger, Uma Thurman, Dame Helen Mirren, Faye Dunaway, Katy Perry, Kate Moss, Marc Jacobs, Ricky Martin, Lea Michele, Michelle Rodriguez, Whoopi Goldberg, amfAR Trustee Harry Belafonte, Naomi Campbell, Heidi Klum, Riccardo Tisci, Adrien Brody, Eva Longoria, Harvey Keitel, Leonardo DiCaprio, Robert De Niro, Robin Thicke, Andrea Bocelli, Dean and Dan Caten, Chris Tucker, Jennifer Garner, Donatella Versace, and Carine Roitfeld.

In 2016, a collection of 1980s classic hits was updated by contemporary artists for *The Time is Now!*—a 14-track compilation album to benefit amfAR. The album features a soulful rendition of Michael Jackson's "Billie Jean" by singer-songwriter Aloe Blacc, and a rendition of New Order's "Bizarre Love Triangle" performed by Sugar for Sugar, consisting of Scarlett Johansson, Julia Haltigan, Holly Miranda, and Kendra Morris. The band Lower Dens, pop rock group DNCE, Dita Von Teese and Sebastien Tellier, and songwriting duo Marian Hill are also featured on the album.



2016 RESEARCH GRANTS, FELLOWSHIPS, AND AWARDS

All projects listed below were awarded funding during the period October 1, 2015, through September 30, 2016.

¹Supported in part with funds provided by the FAIR Foundation

amfAR INSTITUTE FOR HIV CURE RESEARCH

Principal Investigator: Paul Volberding, MD University of California, San Francisco San Francisco, CA \$20,000,000

amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

Predictors of time to viremia with an analytic

treatment interruption Principal Investigator: Timothy Schacker, MD University of Minnesota Minneapolis, MN \$671,846

Allogeneic stem cell transplant in HIV-1-Infected Individuals

Principal Investigator: Annemarie Wensing, MD, PhD University Medical Center Utrecht Utrecht, The Netherlands \$849,910

Development of a humanized superagonist

antibody to human IL-21 for HIV cure Principal Investigator: Di Yu, PhD Monash University Clayton, Australia

\$225.512

INVESTMENT GRANTS

Eradicating the HIV reservoir: Using microfluidics

to exploit killer T cells Principal Investigator: David Weitz, PhD Harvard University Cambridge, MA \$977,114

Tandem latency reversal and suicide prodrugs to

eliminate HIV reservoirs Principal Investigator: Alexander Zelikin, PhD Aarhus University Aarhus, Denmark \$962,510

INNOVATION GRANTS

Analytic treatment interruption to study viral reservoirs and as test for cure in HIV-infected adults on ART

Principal Investigator: Steven Deeks, MD University of California, San Francisco San Francisco, CA \$77,764

Uncovering HIV-1-infected cells: a new path towards a cure

Principal Investigator: Andrés Finzi, PhD Université de Montréal, Centre de Recherche du CHUM Montreal, Canada \$199,997¹

Hormonal control of latent HIV proviruses

Principal Investigator: Jonathan Karn, PhD Case Western Reserve University Cleveland, OH \$200,0001

Quantitative HIV reservoir assay using bar-coded RNA

Principal Investigator: Jonathan Karn, PhD Case Western Reserve University Cleveland, OH \$200,000¹

Optimized assays to measure the latent SIV reservoir in rhesus macaques on ART

Principal Investigator: Maud Mavigner, PhD Emory University Atlanta, GA \$200.000¹

Mechanisms and correlates of post-ART treatment control in SIV-infected macagues

Principal Investigator: Mirko Paiardini, PhD Emory University Atlanta, GA \$200,000¹

Genomic locations of HIV proviruses responsive to latency reversing agents

Principal Investigator: Celsa Spina, PhD University of California, San Diego San Diego, CA \$200,000¹

Discovery of tools to modify the fate of uracilated

HIV DNA in macrophages Principal Investigator: James Stivers, PhD Johns Hopkins University Baltimore, MD \$200,000¹

MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCH

HIV cell-to-cell transmission and the establishment of latency

Principal Investigator: Luis Agosto, PhD Boston Medical Center Boston, MA \$150,000

Rational immunogen design based on study of potent HIV-1 trimer-specific bNAbs

Principal Investigator: Louise Scharf, PhD California Institute of Technology Pasadena, CA \$150,000

Identification, reactivation and elimination of latent HIV-1 in humanized mice

Principal Investigator: Liang Shan, PhD Yale University New Haven, CT \$150,000

Determinants of HIV-1 replication in non-human primate models

Principal Investigator: Amit Sharma, PhD Fred Hutchinson Cancer Research Center Seattle, WA \$146,829

PHASE II KRIM FELLOWSHIP GRANTS

Optimization of anti-HIV antibodies for prevention and therapy

Principal Investigator: Stylianos Bournazos, PhD The Rockefeller University New York, NY \$80,000

Identification of transmitted viral determinants of HIV pathogenesis

Principal Investigator: Dario Dilernia, PhD Emory University Atlanta, GA \$50,000

Identification of a novel HIV-1 restriction factor induced by RNA sensing

Principal Investigator: Henning Hofmann, PhD Robert Koch Institute Berlin, Germany \$80,000

Targeting engineered nanoparticles for therapeutic

purge of HIV-1 reservoir Principal Investigator: Nuria Izquierdo-Useros, PhD Fundación IrsiCaixa Barcelona, Spain \$50,000

SCIENTIFIC MEETINGS

Conference on Cell & Gene Therapy for HIV Cure (2016)

Principal Investigator: Keith Jerome, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA \$10,000

International AIDS Conference 2016

Principal Investigator: Owen Ryan, MPH, MIA International AIDS Society Geneva, Switzerland \$50,000

2016 TREAT ASIA GRANTS AND AWARDS

All projects listed below were awarded funding during the period October 1, 2015, through September 30, 2016.

¹Supported by National Institutes of Health cooperative agreement number U01Al069907 with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, and the National Institute on Drug Abuse

² Supported by National Institutes of Health grant number R01HD073972 funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development

³ Supported with funds provided by the AIDS Life Association

⁴ Supported with funds provided by the Open Society Foundations

⁵ Supported with funds provided by ViiV Healthcare

AUSTRALIA

AUSTRALIA HIV OBSERVATIONAL DATABASE (AHOD) SITES

O'Brien Street Practice

Adelaide, South Australia William Donohue, MBBS \$1,575

Sexual Health and HIV Service In Metro North Brisbane, Queensland Diane Rowling, MBBS, RACP, FAChSHM \$3,600¹

Cairns Sexual Health Service

Cairns, Queensland Darren Russell, MD \$5,2501

RPA Sexual Health Clinic Camperdown, New South Wales David Templeton, MBChB, PhD \$675

Monash Health - Clayton Clayton, Victoria Ian Woolley, MBBS, FRACP \$5,475

D.A. Ellis Pty., Ltd. Coffs Harbour, New South Wales David Ellis, MBBS \$675

East Sydney Doctors Darlinghurst, New South Wales David Baker, MB, ChB, Dip Med, DCH \$7,050¹

Holdsworth House Medical Practice

Darlinghurst, New South Wales Mark Bloch, MD \$5,925¹ St. Vincent's Hospital Sydney Darlinghurst, New South Wales

David A. Cooper, MD \$5,475¹

Taylor Square Private Clinic

Darlinghurst, New South Wales Robert Finlayson, MBBS, DipVen, FAChSHM \$5,025¹

Northern Territory Dept of Health & Community Services, Sexual Health & Blood Borne Virus Program

Darwin, Northern Territory Manoji Gunathilake, MD, MBBS, FAChSHM \$975

Gladstone Road Medical Centre

Highgate Hill, Queensland David Orth, MBBS, DipVen \$5,100¹

Nepean Blue Mountains Local Health District,

Blue Mountains Sexual Health and HIV Clinic Katoomba, New South Wales Eva Jackson, MBBS, FAChSHM \$1,575

Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic

Kingswood, New South Wales Julian Langton-Lockton, MBBS \$1,350

Sexual Health and AIDS Services (SHAIDS)

Lismore, New South Wales David Smith, MBBS, DipVen, FAChSHM, GrapDip BA \$6,075¹

Melbourne Sexual Health Centre

Clayton, Victoria Tim Read, MBBS, DipVen, FRACGP, FAChSHM, EpiDip \$4,425¹

Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital

Melbourne, Victoria Jennifer Hoy, MBBS \$5,5501

Sunshine Coast Hospital and Health Service

Nambour West, Queensland David Sowden, MBBS \$6,375¹

Northside Clinic (Vic) Pty Ltd

North Fitzroy, Victoria

Richard Moore, MBBS \$7,500¹

Royal Perth Hospital

Perth, Western Australia David Nolan, MBBS, FRACP, PhD \$5,175¹

Prahran Market Clinic Pty., Ltd.

Prahran, Victoria Norman Roth, MBBS FAChSHM \$5,775¹

Sydney Sexual Health Centre, Sydney Hospital Sydney, New South Wales Caroline Thng, MBBS, MRCP \$4,275¹

Clinic 468, HNE Sexual Health, Hunter New England Local Health District

Tamworth NEMSC, New South Wales Nathan Ryder, MD \$900

Illawarra Shoalhaven Local Health District

Warrawong, New South Wales Katherine Brown, MD \$1,350

UNSW-Sydney

Sydney, New South Wales Matthew G. Law, PhD IeDEA Asia-Pacific Research Collaboration: TREAT Asia HIV Observational Database & Australia HIV Observational Database \$256,3851

IeDEA Asia-Pacific Research Collaboration: HIV and aging in TAHOD-LITE \$15,0001

leDEA Asia-Pacific Research Collaboration: Cancer Studies \$135,9221

IeDEA Asia-Pacific Research Collaboration: TREAT Asia Pediatric HIV Observational Database \$175,225¹

Effectiveness and tolerability of hepatitis C treatment in HIV co-infected patients in routine care services in Asia \$19,289

CAMBODIA

National Center for HIV/AIDS, Dermatology & STDS / Cambodia National Institute of Public Health

Phnom Penh Ly Penh Sun, MD, MSc TREAT Asia HIV Observational Database (TAHOD) \$20,000¹

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) \$33,666⁵

TREAT Asia Pediatric HIV Observational Database (TApHOD) \$25,000³

New Hope for Cambodian Children

Killeen, TX John Tucker Our Village \$20,743³

Our Village and New Hope House \$50,000

CHINA

Beijing Ditan Hospital Beijing Fujie Zhang, MD, MSPH, PhD TREAT Asia HIV Observational Database (TAHOD) \$16,000¹

Queen Elizabeth Hospital

Hong Kong Man Po Lee, MBBS TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$23,030¹

INDIA

Johns Hopkins University at B.J. Medical College and Sassoon General Hospital Pune

Vidya Mave, MD, MPH Epidemiology of HIV/AIDS and associated comorbidities in a public antiretroviral treatment (ART) clinic in Pune, India \$150,000¹

Chennai Antiviral Research and Treatment Clinical Research Site, YRG CARE Medical Centre, VHS Chennai

Nagalingeswaran Kumarasamy, MBBS, PhD TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$22,040¹

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) $$5,000^5$

TREAT Asia Pediatric HIV Observational Database (TApHOD) \$7,500³

Institute of Infectious Diseases

Pune Sanjay Pujari, MD, AAHIVS, MBBS TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$22,410¹

Wide Angle Social Development Organization Imphal

Rajkumar Nalinikanta Improving HBV & HCV prevention & treatment access in Manipur-Phase IV \$10,060

INDONESIA

Cipto Mangunkusumo General Hospital

Jakarta Nia Kurniati, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) \$7,500³

Evy Yunihastuti, MD, PhD TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$22,900¹

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) \$35,156⁵

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment \$11,603

Indonesia AIDS Coalition

Jakarta Aditya Wardhana Hep C – Know it, get tested and beat it! \$6,583⁴

Sanglah Hospital, Udayana University School of Medicine

Denpasar, Bali Tuti Parwati Merati, MD, PhD TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$22,440¹

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) \$28,264⁵ Ketut Dewi Kumara Wati, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) \$7,500³

Persaudaraan Korban Napza Indonesia (PKNI)

Jakarta Edo Agustian Increasing awareness of hepatitis C with 360 short movie campaign \$2,500⁴

JAPAN

National Center for Global Health and Medicine Tokyo Junko Tanuma, MD, PhD TREAT Asia HIV Observational Database (TAHOD) \$16,000¹

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) \$2,000⁵

MALAYSIA

Hospital Likas Kota Kinabalu Fong Siew Moy, MBBS TREAT Asia Pediatric HIV Observational Database (TApHOD) \$7,500³

Hospital Raja Perempuan Zainab II

Kota Bharu Nik Khairulddin Nik Yusoff, MBBS TREAT Asia Pediatric HIV Observational Database (TApHOD) \$7.500³

Pediatric Institute, Hospital Kuala Lumpur Kuala Lumpur

Thahira A. Jamal Mohamed, MBBS TREAT Asia Pediatric HIV Observational Database (TApHOD) \$7,500³

Penang Hospital

Georgetown Revathy Nallusamy, MBBS TREAT Asia Pediatric HIV Observational Database (TApHOD) \$2,500³

Sungai Buloh Hospital

Sungai Buloh Yasmin Mohamed Gani, MD Study of Transitioning Asian Youth (STAY) Cohort \$14,561⁵

Benedict Lim Heng Sim, MBBS, MRCP TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$16,130¹

University of Malaya

Kuala Lumpur

Raja Iskandar Shah Raja Azwa, MBBS Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) \$45,361⁵

Adeeba Kamarulzaman, MBBS, FRACP, FAMM, FASc

TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$22,390¹

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment \$7,581

NEPAL

Union C

Kathmandu Roshan Sapkota National Awareness Campaign-NEPAL \$7,001

PHILIPPINES

Research Institute for Tropical Medicine Muntinlupa City Rossana Ditangco, MD TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$22,6401

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) \$5,950⁵

SINGAPORE

Tan Tock Seng Hospital Singapore Oon Tek Ng, MBBS TREAT Asia HIV Observational Database (TAHOD)

\$19,250¹ Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)

SOUTH KOREA

\$2,0005

Yonsei University College of Medicine

Seoul Jun Yong Choi, MD, PhD TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$18,290¹

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) \$2,000⁵

TAIWAN

Taipei Veterans General Hospital

Taipei City Wing-Wai Wong, MD TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$23,6701

THAILAND

Chiang Mai University – Research Institute for Health Sciences Chiang Mai

Linda Aurpibul, MD Long-term HBV treatment outcome in HIV-HBV coinfected adolescents receiving tenofovir-containing ARV regimen \$5,230³

Romanee Chaiwarith, MD, MHS TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$23,990¹

Tavitiya Sudjaritruk, MD, ScM, PhD TREAT Asia Pediatric HIV Observational Database (TApHOD) \$15,000³ Peripheral Arterial Diseases among Perinatally HIVinfected Thai Adolescents (PAD study) \$18,423¹

Chiangrai Prachanukroh Hospital

Chiang Rai Rawiwan Hansudewechakul, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) \$15.000³

Human Papillomavirus Infection in Perinatally HIVinfected Adolescents in Asia \$64,043²

Study of Transitioning Asian Youth (STAY) Cohort $\$21,690^{\scriptscriptstyle 3}$

Pacharee Kantipong, MD TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$30,040¹

HIV-NAT / Thai Red Cross AIDS Research Centre Bangkok

Praphan Phanuphak, MD, PhD Examining the prevalence rate and determinants of frailty in the HIV positive and negative Thai populations \$2,545¹

Anchalee Avihingsanon, MD, PhD TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$22,2801

Sivaporn Gatechompol, MD Human Papillomavirus Infection in Perinatally HIVinfected Adolescents in Asia \$65.687²

Watsamon Jantarabenjakul, MD Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents \$4.974

Stephen Kerr, PhD Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI (data management center) \$9,000¹

Study of Transitioning Asian Youth (STAY) Cohort Statistical Analysis Center \$18.0381

Nittaya Phanuphak, MD, PhD Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia (central lab and data manager) \$223,151²

Neovaginal and anal HPV and related diseases among post-operative transgender women \$35,4551

Wasana Prasitsuebsai, MD, MPH Coordinating Center: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children \$32.075⁵

Thanyawee Puthanakit, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) \$15,000³

Peripheral Arterial Diseases among Perinatally HIVinfected Thai Adolescents \$13,4021 Kiat Ruxrungtham, MD Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment \$11,421

Thai Red Cross AIDS Research Centre Bangkok

Tarandeep Anand

The impact of online interventions on the HIV prevention/treatment cascade among MSM and transgender individuals \$21,600

Thanyawee Puthanakit, MD Supporting HIV-infected Adolescents and Youth in Achieving Successful Transition to Adult Care \$30,000³

Mahidol University by Faculty of Medicine Siriraj Hospital

Kulkanya Chokephaibulkit, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) \$15,000³

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI \$2,765¹

Human Papillomavirus Infection in Perinatally HIVinfected Adolescents in Asia \$49,839²

Study of Transitioning Asian Youth (STAY) Cohort $24,958^{\scriptscriptstyle 1}$

Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents \$14,996

Ramathibodi Hospital, Mahidol University

Sasisopin Kiertiburanakul, MD, MHS TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$23,150¹

Srinagarind Hospital, Khon Kaen University Khon Kaen

Pope Kosalaraksa Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents \$12,621

Pagakrong Lumbiganon, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) \$8,100³

Study of Transitioning Asian Youth (STAY) Cohort $\$21,251^{\scriptscriptstyle 5}$

USA

Massachusetts General Hospital

Boston, MA Andrea Ciaranello, MD, MPH Estimating the magnitude of the pediatric and adolescent HIV epidemic in Thailand \$59,951

VIETNAM

Bach Mai Hospital

Hanoi Do Duy Cuong, MD, PhD TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$22,7201

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) \$11,978⁵

Children's Hospital 1

Ho Chi Minh City Tran Ngoc Hanh Dan, MD, MSc

Human Papillomavirus Infection in Perinatally HIVinfected Adolescents in Asia \$8.777²

Truong Huu Khanh, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) \$25,000³

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI \$4,736^{1,3}

Children's Hospital 2

Ho Chi Minh City Do Chau Viet, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) \$20,000³

Hung Vuong Hospital

Ho Čhi Minh City Dang Le Dung Hanh, MD, MA Human Papillomavirus Infection in Perinatally HIVinfected Adolescents in Asia \$13,337²

National Hospital of Pediatrics

Hanoi Nguyen Van Lam, MD, MSc TREAT Asia Pediatric HIV Observational Database (TApHOD) \$20,000³

Study of Transitioning Asian Youth (STAY) Cohort $$8,791^5$

National Hospital of Tropical Diseases

Hanoi Nguyen Van Kinh, MD, PhD TREAT Asia HIV Observational Database (TAHOD) including NCD Data \$22,6101

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) \$26,568⁵

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment \$9,023

Vietnam Network of People Living with HIV (VNP+) Hanoi

Do Dang Dong Increase knowledge about HCV diagnosis, and care and treatment access in the PLHIV and PWID community \$6,500⁴

2016 GMT INITIATIVE GRANTS AND AWARDS

All projects listed below were awarded amfAR funding for the period October 1, 2015, through September 30, 2016.

AMFAR HIV SCHOLARS AWARDS

Designing trans-community led HIV treatment counseling programs suitable for the needs of trans populations in South Africa Principal Investigator: Liesl Theron Gender DynamiX

Cape Town, South Africa \$25,000

Pilot study on HIV among men who have sex with men in Belize

Principal Investigator: Erika Castellanos Collaborative Network of Persons Living with HIV (C-NET+) Belize City, Belize \$25,000

Assessing the efficacy of online HIV home testing support service to increase quarterly HIV testing among MSM

Principal Investigator: Weibin Cheng GZTZ.ORG Guangzhou, China \$25,000

Identifying barriers in accessing care services for low-adherence to ART by MSM and transgender populations in Pakistan

Principal Investigator: Sheryar Kazi NAZ Male Health Alliance Lahore, Pakistan \$25,000

GENERAL GMT INITIATIVE GRANTS AND AWARDS

A training program for HIV research among MSM in low- and middle-income countries

Project Director: Ronald D. Stall, PhD, MPH University of Pittsburgh Pittsburgh, PA \$164,000

2016 PUBLIC POLICY AWARDS

The projects listed below were awarded amfAR funding during the period October 1, 2015, through September 30, 2016.

UNITED STATES

Evaluation of needle exchange distribution policy

Project Director: Susan Sherman, PhD Johns Hopkins University Baltimore, MD \$60,000

Improving the health of young black men who have sex with men (MSM)

Project Director: Jeffrey Crowley Georgetown University Washington, DC \$99,350

PrEP advocacy and demand creation for MSM

Project Director: Emily Bass AIDS Vaccine Advocacy Coalition (AVAC) New York, NY \$50,600

Developing local strategies to implement safe

injection facilities (SIFs) Project Director: Emily Mariko-Sanders Project Inform San Francisco, CA \$10,000

INTERNATIONAL

Increasing access to services for PLHIV who use drugs in the Philippines

Project Director: Cara O'Connor Sustained Health Initiatives of the Philippines Mandaluyong City, Philippines \$30,000



Financial Highlights For the year ended September 30, 2016


Public Support and Revenue	
Public support	\$ 7,104,647
Special events	22,840,383
Planned giving	4,995,589
Government funding	13,063,451
Investment income and other revenue	2,535,019
Total public support and revenue	\$ 50,539,089
Expenses	
Research	\$ 20,306,002
TREAT Asia	5,276,103
GMT Initiative	1,737,688
Public Policy	2,162,183
Public Information	3,892,270
Total program services	\$ 33,374,246
Fundraising	6,054,303
Management and general	2,509,982
Total supporting services	\$ 8,564,285
Total expenses	\$ 41,938,531
Change in net assets	8,600,558
Net assets, beginning of year	53,038,622
Net assets, end of year	\$ 61,639,180

Statement of Financial Position

ts	
\$	19,134,481
	2,020,261
	10,727,662
	2,973,966
\$	3,412,592
\$	80,773,661
	2,976,566
	3,297,004
	10,460,976
\$	64,039,115
	\$


Expenses

Total	\$	41,938,531
Management and general Program	Ŷ	2,509,982 33,374,246
Fundraising	\$	6,054,303



Program Expenses

Total	\$ 33,374,246
Public Information	3,892,270
Public Policy	2,162,183
GMT Initiative	1,737,688
TREAT Asia	5,276,103
Research	\$ 20,306,002



BOARD OF TRUSTEES

Fiscal year 2016

Chairman of the Board Kenneth Cole Chairman Kenneth Cole Productions New York, NY

Founding Chairman Mathilde Krim, Ph.D. Adjunct Professor Mailman School of Public Health Columbia University New York, NY

Vice Chairman Patricia J. Matson Senior Vice President, Communications (ret.) ABC, Inc. New York, NY

Vice Chairman and Treasurer John C. Simons Managing Partner Corporate Fuel Partners, LLC New York, NY

Secretary Mervyn F. Silverman, M.D., M.P.H. President Mervyn F. Silverman Associates Crockett, CA

TRUSTEES

Arlen H. Andelson Senior Partner (ret.) Andelson & Andelson Los Angeles, CA

Harry Belafonte President Belafonte Enterprises, Inc. New York, NY

David Bohnett Chairman David Bohnett Foundation Beverly Hills, CA

Zev Braun President and CEO Braun Entertainment Group, Inc. Beverly Hills, CA

Jonathan S. Canno New York, NY

Donald A. Capoccia Managing Principal BFC Partners Brooklyn, NY

R. Martin Chavez, Ph.D. Chief Information Officer The Goldman Sachs Group, Inc. New York, NY

Jane B. Eisner President The Eisner Foundation Bel Air, CA T. Ryan Greenawalt Managing Director Ramirez & Co. President Harrison Street Productions New York, NY

Regan Hofmann Policy Officer U.S. Liaison Office UNAIDS Washington, D.C.

Michael J. Klingensmith

Publisher and CEO Star Tribune Minneapolis, MN

Kevin McClatchy Chairman of the Board The McClatchy Company Ligonier, PA

Michele V. McNeill, Pharm.D. Chairman McNeill Family Foundation Sarasota, FL

Edward L. Milstein Co-Chairman, Milford Management Co-Chairman, Emigrant Savings Bank Partner, Milstein Properties New York, NY

Cindy D. Rachofsky Philanthropist Dallas, TX

Vincent A. Roberti Chairman, Roberti Global, LLC Managing Director, Roberti Associates Global, LLC Washington, D.C.

Bill Roedy London, UK

Raymond F. Schinazi, Ph.D., D.Sc. Frances Winship Walters Professor of Pediatrics Director, Laboratory of Biochemical Pharmacology Emory University Decatur, GA

Alan D. Schwartz Executive Chairman Guggenheim Partners, LLC New York, NY

Diana L. Taylor Vice Chair Solera Capital, LLC New York, NY

TRUSTEE EMERITUS

Arthur J. Ammann, M.D. President, Global Strategies for HIV Prevention Clinical Professor of Pediatrics University of California, San Francisco San Francisco, CA

IN MEMORIAM

Dame Elizabeth Taylor Founding International Chairman

Sheldon W. Andelson, Esq. Arnold W. Klein, M.D. Mrs. Albert D. Lasker Jonathan M. Mann, M.D., M.P.H. Maxine Mesinger Pauline Phillips Natasha Richardson Allan Rosenfield, M.D. Peter Scott, Esq. Tom Stoddard Joel D. Weisman, D.O.

SPECIAL APPOINTMENTS

Global Campaign Chair Sharon Stone

Global Fundraising Chairman Milutin Gatsby

amfAR AMBASSADORS

Cheyenne Jackson Janet Jackson Milla Jovovich Liza Minnelli Michelle Yeoh

COMMITTEES OF THE BOARD OF TRUSTEES

Executive Kenneth Cole, Chair Michael J. Klingensmith Mathilde Krim, Ph.D. Patricia J. Matson Vincent A. Roberti Mervyn F. Silverman, M.D., M.P.H. John C. Simons

Audit John Simons, Chair R. Martin Chavez, Ph.D. T. Ryan Greenawalt

Board Development Donald A. Capoccia, Co-Chair Patricia J. Matson, Co-Chair Arlen Andelson Bill Roedy Mervyn F. Silverman, M.D., M.P.H.

Communications/Social Media/Marketing Regan Hofmann, Chair Kenneth Cole T. Ryan Greenawalt Patricia J. Matson Kevin McClatchy Vincent A. Roberti Bill Roedy

Compensation and Organizational Development John C. Simons, Chair Michael J. Klingensmith Kevin McClatchy

Finance & Budget

Michael J. Klingensmith, Chair Vincent A. Roberti John C. Simons

Fund Development

Vincent A. Roberti, Chair Arlen Andelson Jonathan S. Canno Donald A. Capoccia T. Ryan Greenawalt Cindy Rachofsky Raymond F. Schinazi, Ph.D., D.Sc.

Investment

Michael J. Klingensmith, Chair R. Martin Chavez, Ph.D. T. Ryan Greenawalt Edward L. Milstein Vincent A. Roberti John C. Simons

SCIENTIFIC ADVISORY COMMITTEE

Daniel C. Douek, M.D., Ph.D. (Chair) Chief, Human Immunology Section Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health

Galit Alter, Ph.D. Associate Professor Department of Medicine Harvard Medical School

Deborah Anderson, Ph.D. Professor of Obstetrics/Gynecology and Microbiology Boston University School of Medicine

Jintanat Ananworanich, M.D., Ph.D. Associate Director for Therapeutics Research U.S. Military HIV Research Program

Warren A. Andiman, M.D.

Professor Emeritus of Pediatrics Co-Director, Yale Adoption Clinic Medical Director, Pediatric AIDS Care Program Yale School of Medicine

Eric Arts, Ph.D. Professor

Department of Microbiology and Immunology The University of Western Ontario

Livio Azzoni, Ph.D. Senior Staff Scientist The Wistar Institute Philadelphia, PA

Michael Betts, Ph.D.

Associate Professor Department of Microbiology Perelman School of Medicine University of Pennsylvania

Jason Brenchley, Ph.D.

Senior Investigator Immunopathogenesis Section National Institute of Allergy and Infectious Diseases National Institutes of Health Dennis R. Burton, Ph.D. Professor Department of Immunology The Scripps Research Institute

Salvatore T. Butera, D.V.M., Ph.D.

Chief Science Officer Scripps CHAVI-ID The Scripps Research Institute

Edward Campbell, Ph.D.

Assistant Professor Department of Microbiology and Immunology School of Medicine Loyola University at Chicago

Alex Carballo-Dieguez, Ph.D.

Co-Director and Senior Research Scientist HIV Center for Clinical and Behavioral Studies New York State Psychiatric Institute Columbia University

Nicolas Chomont, Ph.D.

Assistant Professor Microbiology and Immunology Université de Montréal, Centre de Recherche du CHUM

David B. Clifford, M.D.

Professor Department of Neurology Washington University School of Medicine

C. Budd Colby, Ph.D. Principal Colby Biomedical Ventures

Grant Colfax, M.D. Director Marin Health and Human Services San Rafael, California

Elizabeth Connick, M.D.

Professor of Medicine Chief, Division of Infectious Diseases Department of Medicine University of Arizona

Deborah Jean Cotton, M.D., M.P.H.

Professor of Medicine Boston University School of Medicine

Bryan R. Cullen, Ph.D., D.Sc.

James B. Duke Professor Department of Molecular Genetics and Microbiology Director, Duke University Center for Virology Duke University Medical Center

Susanna Cunningham-Rundles, Ph.D.

Professor Emerita of Research Immunology Department of Pediatrics Weill Cornell Medical College

Richard Thomas D'Aquila, M.D.

The Howard Taylor Ricketts Professor of Medicine Division of Infectious Diseases Director, Northwestern HIV Translational Research Center Feinberg School of Medicine Northwestern University

Steven Deeks, M.D.

Professor Department of Medicine University of California, San Francisco

Sherry Deren, Ph.D. Co-Director Center for Drug Use and HIV Research New York University College of Nursing Roger Detels, M.D., M.S. Professor of Epidemiology School of Public Health University of California, Los Angeles

Carl W. Dieffenbach, Ph.D.

Director Division of AIDS (DAIDS) National Institute of Allergy and Infectious Diseases National Institutes of Health

D. Peter Drotman, M.D., M.P.H.

Editor-in-Chief Emerging Infectious Diseases Centers for Disease Control and Prevention

Anke A. Ehrhardt, Ph.D.

Director Division of Gender, Sexuality, & Health Program for the Study of LGBT Health NYS Psychiatric Institute/Columbia University

Jacob Estes, Ph.D.

AIDS and Cancer Virus Program (ACVP) Frederick National Laboratory for Cancer Research National Cancer Institute

Homayoon Farzadegan, Ph.D.

Professor Department of Epidemiology Johns Hopkins Bloomberg School of Public Health

Dianne M. Finkelstein, Ph.D.

Professor of Biostatistics Harvard School of Public Health Director of the Cancer Center Biostatics Massachusetts General Hospital

Gerald Herbert Friedland, M.D.

Professor and Director AIDS Care Program Department of Internal Medicine Yale School of Medicine

Rémi Fromentin, Pharm.D., Ph.D.

Postdoctoral Researcher Université de Montréal, Centre de Recherche du CHUM

Howard E. Gendelman, M.D.

Professor and Chair, Department of Pharmacology and Experimental Neuroscience Margaret R. Larson Professor of Internal Medicine and Infectious Diseases Director, Center for Neurodegenerative Disorders University of Nebraska Medical Center

Nancy L. Haigwood, Ph.D.

Director and Senior Scientist Division of Pathobiology and Immunology Oregon National Primate Research Center Oregon Health and Science University

Timothy Henrich, M.D.

Assistant Professor of Medicine Division of Infectious Disease University of California, San Francisco

Charles H. Hinkin, Ph.D.

Professor Department of Psychiatry and Biobehavioral Sciences David Geffen School of Medicine University of California, Los Angeles

David Ho, M.D.

Scientific Director, Chief Executive Officer Aaron Diamond AIDS Research Center

Thomas J. Hope, Ph.D.

Professor Department of Cell and Molecular Biology Feinberg School of Medicine Northwestern University

Shiu-Lok Hu, Ph.D.

Professor School of Pharmacy University of Washington

Jonathan Karn, Ph.D.

Director Center for AIDS Research Case Western Reserve University

Vineet KewalRamani, Ph.D.

Chief, Model Development Section HIV Drug Resistance Program National Cancer Institute National Institutes of Health

Hans-Peter Kiem, M.D., F.A.C.P.

Full Member, Clinical Research Division Jose Carreras/E. Donnall Thomas Endowed Chair for Cancer Research Fred Hutchinson Cancer Research Center Seattle, WA

Scott Kitchen, Ph.D.

Assistant Professor of Medicine Division of Hematology and Oncology David Geffen School of Medicine University of California, Los Angeles

Richard Kornbluth, M.D., Ph.D.

President and Chief Scientific Officer Multimeric Biotherapeutics, Inc.

Richard A. Koup, M.D.

Deputy Director, Vaccine Research Center Chief. Immunology Laboratory National Institute of Allergy and Infectious Diseases National Institutes of Health

Nathaniel R. Landau, Ph.D.

Professor Department of Microbiology New York University School of Medicine

Alan L. Landay, Ph.D. Professor and Chairman Department of Immunology and Microbiology Rush-Presbyterian-St. Luke's Medical Center

Michael Lederman, M.D.

Scott R. Inkley Professor of Medicine Associate Director, Center for AIDS Research Case Western Reserve University

Tun-Hou Lee, D.Sc.

Professor of Virology, Emeritus Department of Immunology and Infectious Diseases Harvard School of Public Health

Michael J. Leibowitz, M.D., Ph.D. Professor, Medical Microbiology and Immunology University of California, Davis

Robert J. Levine, M.D.

Professor of Medicine Center for Interdisciplinary Research on AIDS Yale University

Sharon Lewin, F.R.A.C.P., Ph.D.

Director Peter Doherty Institute for Infection and Immunity University of Melbourne

Mathias Lichterfeld, M.D.

Assistant Professor of Medicine Massachusetts General Hospital

Judy Lieberman, M.D., Ph.D.

Senior Investigator Immune Disease Institute Professor of Pediatrics Harvard Medical School

H. Kim Lyerly, M.D.

Professor in Surgery, Immunology, Pathology George Barth Geller Chair of Cancer Research Director of the Center of Applied Therapeutics Duke Cancer Institute Duke University Medical Center

Frank Maldarelli, M.D., Ph.D.

Investigator HIV DRP Host-Virus Interaction Branch National Cancer Institute National Institutes of Health

David M. Margolis, M.D.

Professor of Medicine, Microbiology and Immunology, and Epidemiology School of Medicine University of North Carolina at Chapel Hill

Martin H. Markowitz, M.D.

Professor and Clinical Director Aaron Diamond AIDS Research Center

Kenneth Hugh Mayer, M.D.

Infectious Disease Attending & Director of HIV Prevention Research Beth Israel Deaconess Medical Center

Professor of Medicine Harvard Medical School

Medical Research Director. Co-Chair The Fenway Institute/Fenway Health

Joseph M. McCune, M.D., Ph.D.

Professor of Medicine Chief, Division of Experimental Medicine University of California, San Francisco

Donna Mildvan, M.D.

Chief, Division of Infectious Diseases Department of Medicine Beth Israel Medical Center

Jay A. Nelson, Ph.D.

Professor and Director Vaccine and Gene Therapy Institute Oregon Health and Science University

Una O'Doherty, M.D., Ph.D.

Associate Professor Department of Pathology and Laboratory Medicine Perelman School of Medicine University of Pennsylvania

Nancy Padian, Ph.D., M.P.H.

Adjunct Professor of Epidemiology School of Public Health University of California, Berkeley

Savita Pahwa, M.D.

Professor of Microbiology and Immunology Professor in Pediatrics and Medicine Director of the Miami Center for AIDS Research University of Miami Leonard M. Miller School of Medicine

Tristram G. Parslow, M.D., Ph.D.

William Patterson Timmie Professor and Chair Department of Pathology and Laboratory Medicine Emory University School of Medicine

Matija Peterlin, M.D.

Professor of Medicine, Microbiology and Immunology Department of Medicine University of California, San Francisco

Lynn Pulliam, Ph.D.

Professor Department of Laboratory Medicine and Medicine University of California, San Francisco Veterans Affairs Medical Center

Lee Ratner, M.D., Ph.D.

Professor Department of Medicine Washington University School of Medicine

Andrew Rice, Ph.D.

Professor Department of Molecular Virology and Microbiology Baylor College of Medicine

Charles Rinaldo, Ph.D.

Professor and Chair Infectious Diseases and Microbiology University of Pittsburgh

Melissa Robbiani, Ph.D.

Senior Scientist and Director of Biomedical HIV Research Center for Biomedical Research Population Council

Ruth M. Ruprecht, M.D., Ph.D.

Scientist, Department of Virology and Immunology Southwest National Primate Research Center Director, Texas Biomed AIDS Research Program Texas Biomedical Research Institute

Sarah Schlesinger, M.D. Associate Professor of Clinical Investigation Laboratory of Molecular Immunology The Rockefeller University

Frederick A. Schmitt, Ph.D.

Professor Departments of Neurology, Psychiatry, and Psychology and Behavioral Science Sanders Brown Center on Aging University of Kentucky

Gerald Schochetman, Ph.D.

Senior Director, Diagnostics Research Abbott Laboratories

Robert Turner Schooley, M.D.

Academic Vice Chair Professor and Head Department of Medicine/Division of Infectious Diseases University of California, San Diego

Gail Skowron, M.D.

Professor of Medicine Boston University School of Medicine

Serena Spudich, M.D., M.A.

Associate Professor of Neurology Division Chief, Neurological Infections and Global Neurology Department of Neurology Yale School of Medicine

Leonidas Stamatatos, Ph.D. Member

Fred Hutchinson Cancer Research Center Vaccine and Infectious Disease Division Immunology and Vaccine Development Program Seattle, WA

Mario Stevenson, Ph.D.

Professor of Medicine Chief, Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine

Susana Valente, Ph.D.

Associate Professor Department of Immunology and Microbial Sciences The Scripps Research Institute

Barbara Visscher, M.D., Dr.P.H. Professor of Epidemiology

University of California, Los Angeles

David Vlahov, Ph.D., R.N. Professor of Nursing, Epidemiology, and Biostatistics University of California, San Francisco

David J. Volsky, Ph.D. Professor of Medicine and Par

Professor of Medicine and Pathology Icahn School of Medicine at Mount Sinai

Director of Molecular Virology Laboratory Department of Medicine Mount Sinai St. Luke's and Roosevelt Hospitals

Steven S. Witkin, Ph.D. Professor of Immunology Department of Obstetrics and Gynecology Weill Cornell Medical College

Peter R. Wolfe, M.D.

Associate Clinical Professor David Geffen School of Medicine University of California, Los Angeles

Steven Wolinsky, M.D.

Professor Medicine/Infectious Diseases Feinberg School of Medicine Northwestern University

Richard T. Wyatt, Ph.D.

Professor of Immunology IAVI Center for Neutralizing Antibodies The Scripps Research Institute

Jerome Zack, Ph.D.

Professor Department of Medicine David Geffen School of Medicine University of California, Los Angeles

PROGRAM ADVISORY COUNCIL

Mervyn F. Silverman, M.D., M.P.H. (Chairman) President Mervyn F. Silverman Associates Crockett, CA

Judith D. Auerbach, Ph.D.

Science and Policy Consultant and Professor School of Medicine University of California, San Francisco

David Bloom, Ph.D.

Clarence James Gamble Professor of Economics and Demography Department of Global Health and Population Harvard School of Public Health Boston, MA

Tim Brown, Ph.D.

Senior Fellow The East-West Center Honolulu, HI

Daniel Douek, M.D., Ph.D.

Chief, Human Immunology Section Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health

Daria J. Hazuda, Ph.D.

Vice President, Scientific Affairs for Infectious Disease Merck & Company, Inc. West Point, PA

Kenneth Hugh Mayer, M.D.

Infectious Disease Attending & Director of HIV Prevention Research Beth Israel Deaconess Medical Center

Professor of Medicine Harvard Medical School

Medical Research Director, Co-Chair The Fenway Institute/Fenway Health

Mario Stevenson, Ph.D.

Professor of Medicine Chief, Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine

Jeffrey L. Sturchio, Ph.D.

Senior Partner Rabin Martin New York, NY

Visiting Scholar The Institute for Applied Economics, Global Health and the Study of Business Enterprise Johns Hopkins University

Member

The Council on Foreign Relations Washington, D.C.

Phill Wilson

Chief Executive Officer and President The Black AIDS Institute Los Angeles, CA

MANAGEMENT GROUP

Kevin Robert Frost Chief Executive Officer

Anthony Ancona Vice President and Director, Human Resources

Susan J. Blumenthal, M.D., M.P.A. Senior Policy and Medical Advisor

Bradley Jensen Chief Financial Officer

Rowena Johnston, Ph.D. Vice President and Director, Research

Jeffrey Laurence, M.D. Senior Scientific Consultant for Programs

John F. Logan, Ph.D., J.D. Vice President and General Counsel

Gregorio Millett, M.P.H. Vice President and Director, Public Policy

Eric Muscatell Vice President, Development

AnnMari Shannahan Vice President, Public Information

Annette Sohn, M.D. Vice President and Director, TREAT Asia

amfAR, The Foundation for AIDS Research

NEW YORK 120 Wall Street, 13th Floor New York, NY 10005-3908 (212) 806-1600 (tel) (212) 806-1601 (fax)

WASHINGTON, D.C. 1100 Vermont Avenue, NW Suite 600 Washington, DC 20005 (202) 331-8600 (tel) (202) 331-8606 (fax)

BANGKOK, THAILAND TREAT Asia Exchange Tower 388 Sukhumvit Road, Suite 2104 Klongtoey, Bangkok 10110 Thailand +66 (0)2 663 7561 (tel) +66 (0)2 663 7562 (fax)

www.amfar.org



amfAR meets the BBB Wise Giving Alliance's Standards for Charity Accountability.



